Travere Therapeutics Reports Nine-Month Revenue of $224.56M, Net Loss of $52.34M
Revenue for the first nine months of 2026 rose 36.2% from a year earlier; diluted EPS was a loss of $0.55.
Travere Therapeutics reported revenue of $224.56 million for the first nine months of 2026, up 36.2% from the prior-year period, while net income shifted to a loss of $52.34 million and diluted EPS was a loss of $0.55.Financial Highlights¹ Reported as “Total revenue”. ² Reported as “Net (loss) inco…